THE IMPACT OF ANTIBODY-DRUG CONJUGATES (ADCS) IN THE CHANGING TREATMENT LANDSCAPE OF ADVANCED NSCLC

Chairs
Enriqueta Felip, Barcelona, Spain
Pasi A. Jänne, Boston, MA, USA

SUNDAY, 22 OCTOBER 2023
13:00 - 14:30 CEST, HALL 3 - TOLEDO AUDITORIUM

13:00 Welcome and introduction
Enriqueta Felip, Barcelona, Spain

13:10 Emerging data on the role of ADCs in the clinical care pathways for advanced NSCLC patients
Pasi A. Jänne, Boston, MA, USA

13:30 Improving the safety profiles of ADCs: Early detection and optimal management of toxicities
Maurice Pérol, Lyon, France

13:50 ADCs: Novel combinations with precision therapeutics and the quest for biomarkers
Anne-Marie C. Dingemans, Rotterdam, Netherlands

14:10 Q&A and discussion
All speakers

14:25 Concluding remarks
Pasi A. Jänne, Boston, MA, USA

This educational activity is provided by ESMO and supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca.